Locations:
Search IconSearch
August 28, 2017/Digestive/Case Study

Treatment of “Unresectable” Bilobar Liver Metastasis Using a 2-Stage Approach and HAI: A Case Study

Experienced team, innovative treatment

17-DDI-3877-Quintini-CQD-Hero

By Cristiano Quintini, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Presentation

A 42-year-old female was referred to our institution with large right colon cancer and synchronous bilobar liver metastasis (see presenting CT scan of the liver above). A particular challenge was presented by the lesion encasing the three hepatic veins of the liver (see arrows).

Treatment

The patient received three months of perioperative chemotherapy and was scheduled (three months after the initial presentation) for a two-stage hepatectomy and a combined resection of the primary right colon tumor.

The first surgery included a right hemicolectomy with resection of all the left-sided liver lesions. The surgery was uneventful. On postoperative day 6, the patient underwent a right portal vein embolization with the intent to induce hypotrophy of the right hemi liver and the hypertrophy of the left hemi liver. This approach is used to decrease the risks of postresection liver failure.

Six weeks after the first operation, the patient underwent a right hepatectomy. Given her young age and the extent of the disease, the decision was made to place to also place a hepatic artery infusion (HAI) pump to further decrease her likelihood of recurrence. HAI locoregional treatment is an innovative approach that improves survival after liver resection for metastatic colon cancer. This treatment option is only delivered in selected centers around the world.

The remnant left liver lobe with a catheter inside the gastro-duodenal artery for HAI treatment.

The remnant left liver lobe with a catheter inside the gastro-duodenal artery for HAI treatment.

Outcome

One year after the initial presentation, the patient is free of tumor (see scan below) and receiving routine follow-up scans.

Advertisement

CT scan showing the patient free of tumor.

CT scan showing the patient free of tumor.

Advertisement

Related Articles

Patient speaking with physicians
May 11, 2026/Digestive/Research

Adherence to Lifestyle Changes Peaks One Month After Bariatric Surgery, Study Finds

Patients may benefit from booster appointments, psychological support

Dr. Aminian in OR
May 7, 2026/Digestive/Research

Metabolic Surgery May Reverse MASH Cirrhosis, Paired Biopsy Study Suggests

Research demonstrates cirrhosis regression in one-third of patients, with higher rates using alternative assessment

Dr. Regueiro speaking with patient
May 6, 2026/Digestive/Research

Patients With IBD Who Undergo Colon Cancer Surgery Have Higher Blood Clot Risk

Elevated risk persists for more than a year after surgery, plus more insights from the first study to quantify risk specifically for CRC surgery

Pharmacist filling order
May 5, 2026/Digestive/Research

Fenofibrate-UDCA Combination Therapy Safe and Effective for Primary Biliary Cholangitis

Large, retrospective study indicates improved outcomes after one and five years of treatment

Dr. Bhatt with clinician
April 28, 2026/Digestive/Innovation

Endorobotics Collaborative: A New Era in Gastrointestinal Procedures

Multidisciplinary collaboration is fueling breakthroughs in endoscopic and surgical technology

Dr. Kwan and Dr. Hashimoto performing Laparoscopic Liver Transplant Surgery
April 9, 2026/Digestive/Transplant

Transforming Liver Transplantation at Cleveland Clinic

A surge in transplants, advanced surgical techniques and multidisciplinary collaboration has helped shape and expand the Liver Transplant Program

Patient holding injectable
March 26, 2026/Digestive/Research

New Analysis Examines Long-Term Outcomes of GLP-1 Therapies in Type 1 Diabetes

Retrospective analysis finds lower mortality rates, fewer hospital visits among patients with Type 1 diabetes using GLP-1 Therapies

melanoma
February 13, 2026/Digestive/Case Study

Case Study: An Immunotherapy-First Approach for a 79-Year-Old With Stage IIB Melanoma

Benefits of neoadjuvant immunotherapy reflect emerging standard of care

Ad